CELYAD ONCOLOGY SA Expense From Share-based Payment Transactions With Employees
CELYAD ONCOLOGY SA reported Expense From Share-based Payment Transactions With Employees of EUR 1.62 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-23.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees · last filed 2023-03-23
| Period end | Expense From Share-based Payment Transactions With Employees 12 month |
|---|---|
| 2022-12-31 | 1.62M EUR 20-F · filed 2023-03-23 |
| 2021-12-31 | 2.17M EUR 20-F · filed 2023-03-23 |
| 2020-12-31 | 2.78M EUR 20-F · filed 2023-03-23 |
| 2019-12-31 | 2.77M EUR 20-F · filed 2022-03-24 |
| 2018-12-31 | 3.60M EUR 20-F · filed 2021-03-24 |
| 2017-12-31 | 2.57M EUR 20-F · filed 2020-03-25 |
| 2016-12-31 | 2.85M EUR 20-F · filed 2019-04-05 |
| 2015-12-31 | 796.00K EUR 20-F · filed 2018-04-06 |